ArchiveSeptember 2013

Version 4 of ECTRIMS brain atrophy infographic

Version 4 brain atrophy infographic; comments please. #MSBlog #MSResearch

“The following is version 4 of my brain volume infographic that I will be using at the blogging session at ECTRIMS. I still have time for changes. Any more recommendations would be appreciated. Thank you.”

Imaging the Spinal Cord

Bag AK, Patel BN, Osman S, Roberson GH. Clinico-radiologic profile of spinal cord multiple sclerosis in adults. Neuroradiol J. 2011;24(4):511-8. MRI is extremely useful for the assessment of initial disease burden and to identify the dissemination of the multiple sclerosis (MS) in time and space. The spinal cord is frequently involved in this disease and there has been increasing emphasis of the...

Trying to Distinguish from NMO

Huh SY, Min JH, Kim W, Kim SH, Kim HJ, Kim BJ, Kim BJ, Lee KH.The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.Mult Scler. 2013 Sep  [Epub ahead of print] BACKGROUND:Although neuromyelitis optica (NMO) is a central nervous system (CNS) autoimmune disease distinct from multiple sclerosis (MS). NMO and...

Fingolimod verses injectable 1st-line therapies

Dear doctor which is the most effective DMT? #MSBlog #MSResearch “MSers are always asking me which is the best, most effective MS drug? It is not that simple to answer because we don’t have many head-2-head studies that aren’t biased. For example, even in the TRANSFORMS study that compared fingolimod to interferon-beta (Avonex) study subjects who were enrolled had to have active...

CCSVI is not a causal factor in the pathogenesis of multiple sclerosis.

#MSResearch: CSVI not causal or MS Chambers B, Chambers J, Churilov L, Cameron H, Macdonell R. Internal jugular and vertebral vein volume flow in patients with clinically isolated syndrome or mild multiple sclerosis and healthy controls: results from a prospective sonographer-blinded study. Phlebology. 2013 Sep . [Epub ahead of print] Objectives & Methods: We evaluated internal jugular...

Does eczema increase risk of MS….No.

Deckert S, Kopkow C, Schmitt J. Nona-llergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy. 2013 Sep 21. doi: 10.1111/all.12246. [Epub ahead of print]  The aims of this overview are to synthesize the current evidence of published systematic reviews (SRs) on non-allergic comorbidities of atopic eczema (AE). EMBASE and MEDLINE were searched for SRs published from...

Parkinsons Disease and MS. No increase risk

Nielsen NM, Pasternak B, Stenager E, Koch-Henriksen N, Frisch M. Multiple sclerosis and risk of Parkinson’s disease: a Danish nationwide cohort study.Eur J Neurol. 2013 Sep 19. doi: 10.1111/ene.12255. [Epub ahead of print] BACKGROUND AND PURPOSE:Case reports have observed a co-occurrence of multiple sclerosis (MS) and Parkinson’s disease (PD) and it has been hypothesized that MS...

Re-investigating TNF antagonism likely or not?

Dendrou CA, Bell JI, Fugger L. A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis.Pharmacogenomics. 2013 Sep;14(12):1397-40 Although TNF antagonists are efficacious in treating a range of autoimmune conditions, they exacerbate or even promote multiple sclerosis (MS) – a clinical finding that has been a conundrum for over a decade and has been a source of...

Measuring mobility in MSers

Your legs are made for walking. Lose leg function and it correlates with the impact of MS on your life in general. #MSBlog #MSResearch “Who thought you could relate the social and occupational impact of MS to mobility as determined by the number of steps you take in a single day? So called real-life anchors (unemployment, divorce, assistive device use) resulted in a mean minimal clinically...

Translate

Categories

Recent Posts

Recent Comments

Archives